Addictive Threshold of Nicotine

Sponsor
Yale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06096714
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
36
1
2
36
1

Study Details

Study Description

Brief Summary

To determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, -and reinforcement in smokers with different levels of dependence.

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Detailed Description

The purpose of this project is to determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, and reinforcement in smokers with different levels of dependence. Participants will have an Adaptation Session followed by 4 Test Days. The Adaptation Session will familiarize the participants with study procedures. In each Test Day, a different nicotine dose (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) will be compared to saline for nicotine discrimination, subjective effects, and reinforcement. Participants will first sample the assigned nicotine dose and saline, followed by 4 trials to test their ability to discriminate it from saline. This will be followed by 4 Choice trials where participants will be able to choose between nicotine (at the session-assigned dose) or saline to be administered by the research staff.

Reinforcement will be assessed with the percentage of nicotine choices during the Choice trials. The discrimination is the percentage of correctly identified nicotine and saline infusions. Rewarding effects will be assessed with the "Pleasurable Effects" composite score of the Drug Effects Questionnaire (DEQ).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Health Services Research
Official Title:
Addictive Threshold of Nicotine
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2026
Anticipated Study Completion Date :
Nov 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Nicotine

Adaptation Session followed by 4 Test Days. The Adaptation Session will familiarize the participants with study procedures. In each Test Day, a different nicotine dose (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) will be compared to saline for nicotine discrimination, subjective effects, and reinforcement. Participants will first sample the assigned nicotine dose and saline, followed by 4 trials to test their ability to discriminate it from saline. This will be followed by 4 Choice trials where participants will be able to choose between nicotine (at the session-assigned dose) or saline (A or B).

Drug: Nicotine
Nicotine and saline will be infused using a pump.

Placebo Comparator: saline

Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.

Drug: Nicotine
Nicotine and saline will be infused using a pump.

Outcome Measures

Primary Outcome Measures

  1. correctly identifying nicotine [up to 8 weeks]

    Reinforcement will be assessed with the percentage of nicotine doses chosen during the Choice trials (out of 16), 4 choices per day over four days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 59 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • to contact their primary care provider when necessary.

  • Adults, aged 21 to 59 years. Individuals less than 21 will be excluded because the minimum age for purchasing tobacco products is 21 in our state. The upper age is set at 59 because there are no previous IV nicotine studies that enrolled smokers over the age of 59.

  • Smoking at least for one year and more frequently than once a week, smoking status confirmed with a semi-quantitative urine nicotine test. Smokers will be stratified based on the level of dependence, assessed with the FTND scores (Heatherton et al.

  1. (low or no dependence 4 and moderate or high level of dependence 5.
  • In good health as verified by medical history, screening examination, and screening laboratory tests.

  • For women, report using acceptable birth control methods.

Exclusion Criteria:
  • History of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the participant to be in the study

  • regular current use of certain psychotropic medications (such as mood stabilizers, antipsychotics, or anxiolytics being prescribed to treat bipolar disorder, psychosis or anxiety spectrum disorders, respectively)

  • current untreated alcohol or substance use disorder for any other recreational or prescription drugs other than nicotine

  • for women, pregnant as determined by pregnancy screening, or breastfeeding

  • seeking (or undergoing) treatment for tobacco dependence or smoking.

Contacts and Locations

Locations

Site City State Country Postal Code
1 VA Healthcare System West Haven Connecticut United States 06516

Sponsors and Collaborators

  • Yale University
  • National Institute on Drug Abuse (NIDA)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT06096714
Other Study ID Numbers:
  • 2000036324
  • 2U54DA036151-11
First Posted:
Oct 24, 2023
Last Update Posted:
Oct 24, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 24, 2023